Lymphatic Diseases Clinical Trial
Official title:
Dynamic Contrast Enhanced MR Lymphangiogram Imaging of Lymphatic Anomalies (LA)
Lymphatic Anomalies (LA) is characterized by proliferation of lymphatic tissue causing deterioration of pulmonary function. Understanding changes in lymphatic anatomy in these patients is hindered by the difficulty of imaging the lymphatic system. Dynamic Contrast Enhanced MR Lymphangiogram (DCMRL) may be useful in investigating pathological changes in the lymphatic system.
Lymphatic anomalies (LA) are a spectrum of rare diseases classified into lymphatic tumors and
malformations. Complicated LA cases in the past have been called lymphangiomatosis because of
varied disseminated involvement including soft tissue and viscera such as the spleen, liver
and bone. Pleural effusions and pericardial effusions are often associated with these
lesions. These are now classified into different phenotypes such as Generalized Lymphatic
Anomaly (GLA), Gorham's Stout Disease (GSD) and Kaposiform Lymphangiomatosis (KLA). These
complicated phenotypes can cause massive osteolysis causing a morbidity and mortality from
infection or paralysis or worsening pulmonary function and effusions (GSD, GLA, KLA).
The major cause of mortality and morbidity in these patients is the deterioration of
pulmonary function by chronic chylous effusions and progressive interstitial lung disease.
Unfortunately, little is known about biomarkers, risk stratification or the pathophysiology
of this progression. The understanding of changes in patients' lymphatic anatomy with LA is
hindered by the difficulty of imaging the lymphatic system. Dynamic Contrast Enhanced MR
Lymphangiogram (DCMRL) is a technique that has recently been developed, allowing dynamic MR
imaging of the lymphatic system by injecting gadolinium contrast agent in the groin lymph
nodes.
This technique has been previously used to identify pathological lymphatic perfusion of the
lung parenchyma in patients with plastic bronchitis and neonatal chylothorax. Based on these
imaging findings, a treatment algorithm has been designed and used to successfully treat the
majority of those patients with these conditions.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02497131 -
Study on the Role of Brentuximab Vedotin as Single Agent in the Treatment of Relapsed/Refractory CD30+ PTCL Patients
|
Phase 2 | |
Recruiting |
NCT01451502 -
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
|
N/A | |
Active, not recruiting |
NCT03264131 -
BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma
|
Phase 2 | |
Completed |
NCT03744676 -
A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting (TRANSCEND-OUTREACH-007)
|
Phase 2 | |
Completed |
NCT02335242 -
Sildenafil for the Treatment of Lymphatic Malformations
|
Phase 2 | |
Completed |
NCT03135535 -
Micro-mobile Foot Compression and Diabetic Foot
|
Phase 2 | |
Active, not recruiting |
NCT05441943 -
Lymphaticovenous Anastomosis as Treatment for Lymphedema
|
N/A | |
Recruiting |
NCT06267807 -
Lymphatic Phenotype in Noonan Syndrome Spectrum Disorders
|
N/A | |
Withdrawn |
NCT05431179 -
A Study of Zilovertamab and Ibrutinib in Patients With Relapsed or Refractory Mantle Cell Lymphoma
|
Phase 3 | |
Recruiting |
NCT05731141 -
A Prospective Natural History Study of Lymphatic Anomalies
|
||
Recruiting |
NCT03696784 -
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
|
Phase 1 | |
Completed |
NCT03709407 -
"Effects of Manual Lymphatic Drainage in the Neck in Healthy Subjects. Experimental Randomized Crossover Study"
|
N/A | |
Active, not recruiting |
NCT02663297 -
Administration of T Lymphocytes for Prevention of Relapse of Lymphomas
|
Phase 1 | |
Completed |
NCT05683444 -
Octreotide Improves Human Lymphatic Fluid Transport a Translational Trial
|
Early Phase 1 | |
Completed |
NCT02960841 -
Effectiveness of Intracavitary Manual Lymphatic Drainage
|
Phase 4 | |
Recruiting |
NCT05263583 -
Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma
|
Phase 2 | |
Terminated |
NCT02499627 -
Bendamustine Plus Brentuximab Vedotin in HL and CD30+ PTCL in First Salvage Setting
|
Phase 2 | |
Recruiting |
NCT03373019 -
Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
|
Phase 2 | |
Recruiting |
NCT03602157 -
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
|
Phase 1 | |
Recruiting |
NCT02690545 -
Study of CD30 CAR for Relapsed/Refractory CD30+ HL and CD30+ NHL
|
Phase 1/Phase 2 |